secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269548
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q3 cash $209M, raises $242.8M; MM120 Phase 3 GAD/MDD readouts on track for 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $209.1M at Sept 30, 2025; net proceeds of $242.8M from Oct 31 offering extend runway into 2028.
- R&D expenses $31.0M in Q3 2025 vs $17.2M in Q3 2024, driven by MM120 program costs.
- Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) 2H 2026.
- Phase 3 Emerge (MDD) topline data accelerated to mid-2026 (from 2H 2026); Ascend (MDD) to initiate mid-2026.
- Phase 2a of MM402 for ASD to start Q4 2025; MM120 Phase 2b published in JAMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312525269548/0001193125-25-269548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312525269548/mnmd-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer